Arthritis Psoriatic

• EMA approval · 2026-08-26
  EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG

  Regulatory authorization for Skyrizi (risankizumab) by AbbVie Deutschland GmbH & Co. KG across multiple inflammatory diseases.

• EMA withdrawal · 2026-07-31
  EMA Withdrawn: Qoyvolma (ustekinumab) — Celltrion Healthcare Hungary Kft.

  The EMA has withdrawn Qoyvolma (ustekinumab) from the market.

• CLINICAL_TRIALS trial_result · 2025-12-08
  Clinical Trial Update: Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent [Phase 3]

  Phase 3 trial update evaluating guselkumab in active psoriatic arthritis patients with inadequate response/intolerance to one prior anti-TNF…

• CLINICAL_TRIALS trial_result · 2021-08-11
  Clinical Trial Update: A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis [Phase 4]

  Phase 4 pilot trial investigating Technetium-99m methylene diphosphonate in the treatment of psoriatic arthritis has completed.

• CLINICAL_TRIALS trial_result · 2021-03-03
  Clinical Trial Update: Low Dose Naltrexone for Chronic Pain From Arthritis [Phase 2]

  Phase 2 clinical trial of low-dose naltrexone for chronic pain from arthritis has completed; results posted in 2021.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2021-01-29
  EMA Withdrawn: Halimatoz (adalimumab) — Sandoz GmbH

  The EMA withdrew Halimatoz (adalimumab) supplied by Sandoz GmbH from the market.

• CLINICAL_TRIALS trial_result · 2020-11-05
  Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis [Phase 3]

  Phase 3 trial evaluating subcutaneous guselkumab for active psoriatic arthritis has completed with posted results.

• EMA withdrawal · 2020-03-25
  EMA Withdrawn: Kromeya (adalimumab) — Fresenius Kabi Deutschland GmbH

  EMA has withdrawn Kromeya (adalimumab) from Fresenius Kabi Deutschland GmbH, effective 2019, affecting multiple inflammatory diseases.